NCT02921022View on ClinicalTrials.gov

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Pancreatic CancerAdvanced Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Gemcitabine

DRUG

Nab-paclitaxel

DRUG

PEGPH20

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

18103

Lehigh Valley Health Network, Allentown

33143

Miami Cancer Institute, Miami

06102

Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford

Unknown

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

Halozyme Therapeutics
All Listed Sponsors
collaborator

Halozyme Therapeutics

INDUSTRY

collaborator

Miami Cancer Institute

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02921022 - Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter